News Briefing for Health Care Sector Companies: Embark Holdings, Vitamin Shoppe, MusclePharm, Repros Therapeutics, Unilife and

   News Briefing for Health Care Sector Companies: Embark Holdings, Vitamin
         Shoppe, MusclePharm, Repros Therapeutics, Unilife and Pfizer

  PR Newswire

  CORAL SPRINGS, Florida, April 11, 2013

CORAL SPRINGS, Florida, April 11, 2013 /PRNewswire/ -- issues market news report for today's Active HealthCare
Companies: Embark Holdings, Inc., Vitamin Shoppe, Inc. (NYSE: VSI),
MusclePharm Corporation, Repros Therapeutics Inc.(NASDAQ: RPRX), Unilife
Corporation (NASDAQ: UNIS) and Pfizer Inc. (NYSE: PFE)

Embark Holdings, Inc. a leader in providing research, evaluation and
acquisition services to businesses throughout the world, announced acquiring
100% of Muscle Warfare, Inc. ( ) a company that
develops, manufactures, and markets sports nutrition products of the highest
quality for athletes around the world in all sports, including both
professional and amateur enthusiasts. The acquisition consisted of preferred
shares in Embark Holdings, Inc. Muscle Warfare products are certified banned
substance free by the World Anti-Doping Agency ("WADA") standards and are
tested in one of the most elite testing labs in the world called HFL Sport
Science, the world's largest and most experienced sports test laboratory. The
HFL laboratory is ISO Certified and accredited for forensic testing and meets
or exceeds world anti-doping agency standards and requirements. The company's
processes ensure that the product offerings distributed are free of
inadvertent contaminants and are not deliberately spiked with contaminant
compounds by many raw material manufacturers. Muscle Warfare is now
distributing product in approximately 550+ Vitamin Shoppe (NYSE: VSI) stores
Nationwide. Also, they have a very strong partnership with Europa, the largest
independent sports nutrition distributor in the  U.S. ; along with many Large
scale International Clients, which it believes will help continue our growth
trajectory . Read the full press release at

Vitamin Shoppe, Inc. (NYSE: VSI ) , a leading multi-channel specialty
retailer of nutritional products, announced this week the company's Senior
Vice President, General Counsel & Corporate Secretary, Jean Frydman, has been
selected as a finalist in the public company with revenues over $1 billion
category in the 2013 NJBIZ General Counsel of the Year Awards program. The
annual NJBIZ award program recognizes New Jersey's leading General Counsels,
Chief Legal Officers and corporate compliance officers and their key
achievements for the companies they work for. Ms. Frydman joined the Vitamin
Shoppe in May 2012, and during her tenure has guided the company through the
acquisition of Super Supplements, the largest acquisition in the company's
history. She has also guided the company through the lease process for new
corporate office space and a new distribution center planned to open this
summer during a period of increasing growth for the company.

MusclePharm Corporation, a nutritional supplement company focused on active
lifestyles, announced today it continues to see strengthening demand for its
line of branded sports nutritional products in international markets. During
the year ended December 31, 2012, gross sales of MusclePharm products in
international markets grew to approximately $27 million, an increase of over
550% as compared to gross sales of $4 million in 2011. In 2012, international
sales accounted for approximately 35% of overall sales, up from 19% in 2011.

Repros Therapeutics Inc. (NASDAQ: RPRX ) announced this week two patents
representing potentially large commercial indications for its drug Androxal
have been issued. The two patents deal with the metabolic consequences of low
testosterone and the positive outcomes associated with restoration of
testicular function exhibited by Androxal. The 8,377,991 patent specifically
covers treatment of Type 2 diabetes, an area of high unmet medical need. The
991 issuance and patent life should have a positive impact on Androxal's
long-term commercial potential.

Unilife Corporation (NASDAQ: UNIS ) announced yesterday the signing of a
Customization and Commercial Supply Agreement with a U.S. pharmaceutical
company for the EZMix(TM) dual-chamber syringe. Unilife will supply the
Customer with a customized device from its EZMix platform of dual-chamber
delivery systems for use with a lyophilized drug that requires mixing at the
time of injection. The Drug, which is a proprietary version of an approved
therapy, is entering late-stage clinical development with the Customer
planning an accelerated pathway to U.S. regulatory approval.

Pfizer Inc. (NYSE: PFE ) says U.S. regulators have classified its
experimental pill for advanced, often-deadly breast cancer as a breakthrough
therapy. That's done to speed up development and review of treatments seen as
big advances. Palbociclib is in late-stage testing as an initial treatment
for the biggest subgroup of postmenopausal women with advanced breast cancer -
those in whom tumor growth is fueled by the hormone estrogen but not by a
growth-promoting protein called HER2.   is leading provider of third party publishing & 
news dissemination services .  If you would like more information regarding
our news coverage solutions, please visit
  for more details.  Get an edge on the market with our  Premium News
Alerts   that are FREE for a limited time at . Follow us on Facebook:   and Twitter:

DISCLAIMER:FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:

Company: FN Media Group, LLC Contact email:
U.S. Phone: +1(954)345-0611 URL:
Press spacebar to pause and continue. Press esc to stop.